Efficacy and Safety of Aspirin for Primary Cardiovascular Risk Prevention in Younger and Older Age: An Updated Systematic Review and Meta-analysis of 173,810 Subjects from 21 Randomized Studies
April 1, 2022
The debate insofar as aspirin in primary prevention of death has raged for decades. This very large study demonstrates potential benefit for younger population (7% benefit), but in general there is no significant impact in all-cause mortality and risk of major bleeding was noticeable. In my opinion, it is reasonable to consider low dose aspirin for individuals 50-60 years of age, especially with risk factors for CV disease.
